Search clinical trials for: Proellex Formulation B

Total 8054 results

Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Vaginal Administration

Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Oral Administration

Healthy

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
Repros Therapeutics Inc.

Terminated

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Uterine Fibroids

United States
GlaxoSmithKline

Completed

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Multiple Sclerosis

Poland, Germany, Czechia
Medicines for Malaria Venture
Richmond Pharmacology Limited

Completed

A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers

Malaria

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

Healthy Subjects

Netherlands
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Healthy | Gastric Retention

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Chronic Hepatitis C

United States
Repros Therapeutics Inc.

Terminated

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Renal Impairment

United States
ViiV Healthcare

Recruiting

A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

HIV Infections

United Kingdom
Pfizer

Terminated

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

Respiratory Tract Infection

United States, Australia
Idorsia Pharmaceuticals Ltd.

Completed

Bioequivalence Study of Different Aprocitentan Tablet Formulations

Healthy Subjects

Czechia
Gesynta Pharma AB
CTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden AB

Completed

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Pharmacokinetic

Sweden
Pfizer

Completed

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

Healthy

United States
Pfizer

Recruiting

Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

Healthy Subjects | Healthy Participants

United States
Repros Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Uterine Fibroids
Bristol-Myers Squibb

Completed

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Heart Failure

United States
Pfizer

Completed

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

Respiratory Tract Infections

United States
ViiV Healthcare
GlaxoSmithKline

Not yet recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections

United States
GlaxoSmithKline

Completed

Bioequivalence and Food Effect Study in Healthy Volunteers

Sleep Initiation and Maintenance Disorders

Italy
AbbVie

Completed

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

ABBV-154

United States
Repros Therapeutics Inc.

Completed

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Impaired Liver Function

United States
Repros Therapeutics Inc.

Withdrawn

Open-Label Extension Study to ZPE-202

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Crossover Study of the Safety and PK Properties of Proellex®

Pharmacokinetics

United States
Repros Therapeutics Inc.

Completed

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

ABSORPTION | METABOLISM | EXCRETION

United States
Repros Therapeutics Inc.

Withdrawn

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Uterine Fibroids

United States, Brazil
Repros Therapeutics Inc.

Completed

Proellex Pharmacokinetics Bridging Study

Healthy

United States
Alcon Research

Completed

Evaluation of Safety and Tolerability of Ocular Lubricants

Dry Eye

Australia
Allergan

Completed

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

Healthy Volunteers

United States
Janssen Sciences Ireland UC

Completed

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Healthy

United Kingdom
Allergan

Completed

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Erythema | Rosacea

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
AstraZeneca

Completed

A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition

Chronic Kidney Disease

Germany
Intec Pharma Ltd.

Completed

Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep

Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep

Israel
Allergan

Completed

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States
Bayer

Completed

A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein

Biological Availability

Netherlands
Northwestern University
Ann & Robert H Lurie Children's Hospital of Chicago

Completed

Comparison of Two Salicylic Acid Formulations

Acne Vulgaris

United States
Repros Therapeutics Inc.

Terminated

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

A Safety and Pharmacokinetic Study of Proellex® (PK)

Healthy

United States
Repros Therapeutics Inc.

Completed

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Pfizer

Completed

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Healthy

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers

Coronary Artery Disease (CAD)

United Kingdom
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Uterine Fibroids

United States
H. Lundbeck A/S

Completed

Bioequivalence Study of Idalopirdine Tablets 60 mg

Healthy

United Kingdom
Repros Therapeutics Inc.

Terminated

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States

3

Subscribe